Avantor, Inc. filings document operating results, financial condition and segment reporting for a life science tools company serving life sciences and advanced technology customers. Recent 8-K reports furnish quarterly and annual earnings releases, non-GAAP measures such as adjusted EBITDA and free cash flow, guidance references, and the realignment of reportable segments into VWR Distribution & Services and Bioscience & Medtech Products, including recast historical segment information.
The company’s proxy and current reports also disclose governance matters, director elections, board committee assignments, executive officer transitions, compensation arrangements and annual meeting materials. These filings frame Avantor’s public-company disclosures around its product and services portfolio, leadership structure and shareholder voting matters.
Avantor, Inc. EVP, Chief Legal & Compliance Claudius Sokenu reported a direct award of 62,305 restricted stock units on October 30, 2026. The units vest in three equal annual installments beginning October 30, 2027.
Avantor, Inc. EVP, Chief HR Officer Brittany Hankamer received a grant of 46,728 restricted stock units on October 30, 2026. The units vest in three equal annual installments beginning October 30, 2027. Her reported direct holdings following the transaction were 295,592 shares.
Avantor, Inc. granted its Executive Vice President, Chief Legal and Compliance Officer and Secretary, Claudius Sokenu, 62,305 restricted stock units on October 31, 2026. The Compensation and Human Resources Committee approved the special long-term incentive award on October 30, 2026, citing his overall performance and contributions, including leadership in litigation and regulatory management, dispute resolution and corporate governance. The RSUs were granted under Avantor’s 2019 Equity Incentive Plan and vest in equal installments on the first three anniversaries of the grant date, subject to Mr. Sokenu’s continued employment through each applicable vesting date.
Avantor, Inc. (AVTR) reported third-quarter net sales of $1,698.3 million, up 4.6% from $1,623.8 million, including 5.2% organic growth. Net income was $203.4 million, compared with a $711.8 million loss a year earlier, when the company recorded a $785.0 million non-cash goodwill impairment charge. Adjusted EBITDA was $256.9 million versus $267.9 million; gross margin was 31.5%, down from 32.4%.
For the first nine months, Adjusted EBITDA fell 10.6% to $730.6 million from $817.3 million, and operating cash flow was $432.0 million versus $471.1 million. At September 30, 2026, total liquidity was $1,844.2 million and total debt was $3,683.8 million. Management said a material non-cash goodwill impairment could be required if market conditions deteriorate further or VWR Distribution projections are reduced.
On July 14, 2026, Avantor repaid its Euro term loan B-6 and issued a B-7 tranche at EURIBOR plus 2.00%, versus 2.50%. Principal outstanding immediately before and after was $427.1 million; the B-7 maturity is October 9, 2032.
Avantor, Inc. reported third-quarter 2026 net sales of $1,698.3 million, up 4.6% year over year, with organic sales growth of 5.2%. GAAP net income was $203.4 million, compared with a $711.8 million net loss a year earlier; adjusted net income was $146.4 million versus $151.1 million. Diluted GAAP EPS was $0.30 and adjusted EPS was $0.22. Adjusted EBITDA was $256.9 million, with a 15.1% margin.
Operating cash flow was $195.1 million and free cash flow was $156.2 million, compared with $207.4 million and $171.7 million, respectively, in the prior-year quarter. Nine-month adjusted EBITDA was $730.6 million versus $817.3 million. Avantor raised 2026 organic revenue growth guidance to +0.75% to +1.25%, adjusted EPS guidance to $0.81 to $0.83, and free cash flow guidance to $525 million to $550 million, excluding cash restructuring costs; adjusted EBITDA margin guidance remains 14.8% to 15.3%.
Avantor, Inc. EVP and CFO Todd W. Garner received 49,688 restricted stock units and options covering 138,632 common shares on September 21, 2026. The reported post-grant positions were 49,688 restricted stock units and options covering 138,632 shares. The restricted stock units vest in two equal annual installments and the options in three equal annual installments, both beginning September 21, 2027. The options have an exercise price of $16.61 per share and expire September 21, 2036. No Rule 10b5-1 plan is reported.
Avantor, Inc. (AVTR) announced that Todd Garner has been appointed Executive Vice President and Chief Financial Officer, effective September 21, 2026, and will serve as the company’s principal financial officer and member of its Executive Leadership Team. Garner will oversee global finance functions including FP&A, accounting, treasury, tax, investor relations and internal audit.
Avantor entered into an employment letter with Garner on September 17, 2026, providing a $700,000 annual base salary, an annual cash bonus opportunity targeted at 80% of base salary (pro-rated for 2026), and a one-time $150,000 cash signing bonus subject to repayment if he departs within one year of the commencement date. He will receive an initial long-term equity grant with a target value of $1,500,000, split equally between restricted stock units vesting over two years and stock options issued at a 10% premium to the grant-date closing price, vesting over three years. In future years, he will be eligible for an annual long-term incentive grant targeted at $3,000,000. Steven Eck will cease serving as Interim Chief Financial Officer upon Garner’s commencement but will continue as Senior Vice President and Chief Accounting Officer.
Avantor, Inc. (AVTR) appointed Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026, and he will serve as the company’s principal financial officer and join its Executive Leadership Team. Garner previously served as CFO of CONMED Corporation and held senior finance roles at C.R. Bard.
Under an employment letter dated September 17, 2026, Garner will receive an annual base salary of $700,000, a target annual bonus equal to 80% of base salary (pro-rated for 2026), and a one-time $150,000 cash signing bonus subject to repayment if he departs within one year of the commencement date. He will receive an initial long-term equity grant with a target value of $1,500,000, split equally between restricted stock units vesting over two years and stock options, issued at a 10% premium to the grant-date closing price, vesting over three years. He will be eligible for future annual long-term incentive grants targeted at $3,000,000 and to participate in Avantor’s Executive Severance and Change in Control Plan. Steven Eck will cease serving as Interim CFO on the commencement date but will continue as Senior Vice President and Chief Accounting Officer.
Avantor, Inc. (AVTR) filed an amended current report to update details about the previously announced transition and planned departure of Benoit Gourdier, Executive Vice President, Bioscience and Medtech Products. Avantor, through its subsidiary VWR International, LLC, and Mr. Gourdier entered into a Transition Agreement on August 21, 2026, under which he will remain employed through October 14, 2026, when his employment will end. If he remains employed and complies with the Transition Agreement through that date, he will receive severance benefits materially consistent with the company’s Executive Severance and Change in Control Plan, as described in Avantor’s March 27, 2026 proxy statement.